Drugs / THR-18
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01253512 | Mar → Dec 2011 | ischemic stroke | Thrombotech Ltd. | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01957774 | Oct 2013 → Nov 2014 | stroke disorder | D-Pharm Ltd. | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT02572336 Comparator | Oct 2015 → Mar 2016 | ischemic stroke | D-Pharm Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | THR-18 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02572336 ↗ |
| Modality | Peptide | “18-mer peptide” NCT01957774 ↗ |
| Route | Intravenous | “after they are injected, at the same time, into a vein” NCT01957774 ↗ |